| Literature DB >> 32311028 |
Loes van Dam1, Tobias B Dansen1.
Abstract
It is well established that both an increase in reactive oxygen species (ROS: i.e. O2•-, H2O2 and OH•), as well as protein aggregation, accompany ageing and proteinopathies such as Parkinson's and Alzheimer's disease. However, it is far from clear whether there is a causal relation between the two. This review describes how protein aggregation can be affected both by redox signalling (downstream of H2O2), as well as by ROS-induced damage, and aims to give an overview of the current knowledge of how redox signalling affects protein aggregation and vice versa. Redox signalling has been shown to play roles in almost every step of protein aggregation and amyloid formation, from aggregation initiation to the rapid oligomerization of large amyloids, which tend to be less toxic than oligomeric prefibrillar aggregates. We explore the hypothesis that age-associated elevated ROS production could be part of a redox signalling-dependent-stress response in an attempt to curb protein aggregation and minimize toxicity.Entities:
Keywords: amyloid; protein aggregation; reactive oxygen species; redox signalling
Mesh:
Substances:
Year: 2020 PMID: 32311028 PMCID: PMC7200635 DOI: 10.1042/BST20190054
Source DB: PubMed Journal: Biochem Soc Trans ISSN: 0300-5127 Impact factor: 5.407
Figure 1.Energy landscape in proteostasis.
Newly synthesized peptides sample different conformations during protein folding, on their way downhill to the most thermodynamically favourable state. Energetically trapped, partially unfolded or sub-optimally folded intermediates may accumulate as they need to cross energy barriers to reach their native, low energy state. Non-native interactions may lead to protein aggregation, thereby interfering with the protein folding process. The proteostasis network can assist in lowering energy barriers and preventing non-native interactions. As indicated by the yellow circles, H2O2-mediated redox signaling or ROS-dependent damage helps to overcome the transition state between intermediates of the proteostasis network.
Figure 2.The proteostasis network.
Cells employ several mechanisms to maintain proteins integrity and minimize non-native or harmful protein conformations. Mechanisms are in place for proteome quality control. Redox signalling participates in proteostasis by modulating the folding, misfolding, (dis)aggregation and the extent of toxicity of protein aggregates. References to examples of the various steps are indicated in numbers. Note that in some cases it is not clear from the literature what exact step in aggregation is affected, or whether multiple steps are affected, and in this case, the reference is denoted at the first transition from native to partially unfolded.
Summary of redox-regulated protein aggregates
| Protein | Abbreviation | Normal function | Involved residue (Cys) | Modification | Consequence(s) | Type of aggregation | Related pathologies | Reference |
|---|---|---|---|---|---|---|---|---|
| AMP-activated protein kinase | AMPK-alpha | Energy metabolism | C130 and C174 | Disulfide | Inactivation | Soluble aggregates | Cardiopathologies, energy starvation | [ |
| Apolipoprotein A-I | APOA1 | Cholesterol transport | Methionines | Methionine oxidation | Partial unfolding, fibrillization and inactivation | Amyloid | APOA1 amyloidoses and atherosclerosis | [ |
| APP/Amyloid-β | Aβ | Unknown | M35 | Methionine oxidation | Required for pro-oxidative activity | Amyloid | Alzheimer's | [ |
| Ataxin-2 | ATXN2 | TORC1 inhibition | Methionines | Methionine oxidation | Oxidation reverses aggregation, functional regulation of activity | LLPS, amyloid | Spinocerebellar atrophy, ALS | [ |
| Cellular prion protein | PrPC and PrPSC | Synaptic function | C179 and C214 | Disulfide exchange | Reduction of PrPC induces aggregation of PrPSC polymer | Amyloid | Transmissible spongiform encephalopathies | [ |
| Cyclin-dependent kinase inhibitor 2A | p16INK4A | Cell cycle regulation, senescence | C72 | Homodimerisation | Inactivation | Amyloid | Cancer | [ |
| Endostatin | COL18A1 | Angiogenesis inhibition | C33, C135, C165 and C173 | Disulfide | Prevents aggregation | Amyloid | Alzheimer's | [ |
| Fas ligand | FasL | Apoptosis, inflammation | Methionines | Methionine oxidation | Multimerization and aggregation enhanced biological activity | Unknown | Acute lung injury | [ |
| Glyceraldehyde-3-phosphate dehydrogenase | GAPDH | Glycolysis | M46 | Methionine oxidation, disulfides | Local conformational change promotes disulfide cross-linking and aggregation | Amyloid | Alzheimer's, motor neuron disease | [ |
| Growth hormone (recombinant) | hGH | (Therapeutic protein production) | M14 and M125 | Methionine oxidation | Lower stability | Unknown | GH deficiency | [ |
| human Islet Amyloid Polypeptide | hIAPP | Insulin/glucagon secretion, gastric emptying | C2 and C7 | Disulfide | Prevents aggregation | Amyloid | Type 2 diabetes | [ |
| Huntingtin | HTT | Unknown | M8 | Post-aggregation methionine oxidation | Controls interaction between aggregates | Amyloid | Huntington disease | [ |
| C115 and C119 | Disulfide mediated oligomerization | Oxidation-dependent soluble toxic oligomers, slower clearance | Soluble oligomeric aggregates | [ | ||||
| Interferon-β1a (recombinant) | IFNβ1a | (Therapeutic protein production) | Many residues (M, H, F, W, Y) | Cross-linking | Lower stability | Unknown | [ | |
| Mitochondrial GrpE protein homologue | MGE1 | Proteostasis, HSP70 cochaperone | M155 | methionine oxidation | Inactive HSP70 but targeting it to unfolded proteins | Amyloid | Myopathies | [ |
| Sequestosome-1 | SQSTM1/p62 | Autophagy | C105 and C113 | Disulfide mediated oligomerization | More autophagy, cell survival | Insoluble aggregates, LLPS | ALS | [ |
| Superoxide dismutase 1 | SOD1 | Dismutation of superoxide | C111 | Disulfide-linked dimerization | Oligomerization and subsequent fibril formation | Oligomeric, amyloid and amorphous | ALS | [ |
| Transthyretin | TTR | Thyroid hormone binding | C10, M1 and M13 | Cysteine sulfonic acid, methionine sulfoxide | Tetramer dissociation and aggregation | Amyloid | Senile systemic amyloidosis | [ |
| Tryptophan hydroxylase 2 | TPH2 | Serotonin biosynthesis | Any out of 13 cysteines | Disulfide, cross-linking | Misfolding, intra- and intermolecular disulfide bond formation, protein inactivation | Unknown, disulfide cross-linked oligomers | Parkinson's | [ |
| Vinisin-like protein 1 | VSNL1 | Calcium sensing | C187 | Disulfide-linked homodimerization | Reduced levels of functional protein | Amyloid, disulfide cross-linked oligomers | ALS, AD | [ |
| y-synuclein | SNCG | Neurofilament network integrity | M38 and Y39 | Oxidation-dependent oligomerization | Aggregation and seeding for α-synuclein aggregation | Amyloid | Parkinson's | [ |
| β2-microglobulin | β2M | MHCI light chain | C25 and C80 | Disulfide reduction, disulfide exchange, post-aggregation oxidation | Aggregation, post-aggregation stabilization | Amyloid | Hemodialysis-related amyloidosis | [ |
| γ-crystallins | CRYG | Lens transparency | C32 and C41 | Intramolecular disulfide | Destabilizes its N-terminal domain, stabilizes an intermediate which is prone to aggregation | Amorphous | Cataract | [ |
| κ-casein | CSN3 | Milk protein | M95 and M106 | Methionine oxidation | Increased aggregation, increased toxicity | Amyloid | Corpora amylacea | [ |
Figure 3.Redox regulation of proteostasis.
Redox signalling modulates proteostasis in many ways. Among its roles are the regulation of protein folding, unfolding/aggregation, toxicity reduction and damage response.